| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 28, 2022
World Stroke Congress 2022: DiVERT Stroke Study shows significant differences in post-stroke workflow protocols and cardiac monitoring
-
Oct 24, 2022
-- More than two dozen GI GeniusTM intelligent endoscopy modules active across seven MNGI Digestive Health clinics will improve the accuracy of colonoscopies for Minnesotans --
-
Oct 14, 2022
Study data show clinically meaningful impact on quality of life and disease severity, even in the most complex patients
-
Oct 10, 2022
-- FORTUNE puts Medtronic among top 50 global companies having a positive social impact through core business strategy
-
Oct 5, 2022
-- Veterans will have access to GI Genius™ intelligent endoscopy modules across the country that use AI help to detect colorectal polyps during colonoscopy --
-- Among Veterans, Colorectal cancer is of the five most frequently diagnosed cancers and a leading cause of cancer-related deaths --
-
Sep 28, 2022
-- Nexpowder™* provides gastroenterologists improved visibility, controls upper gastrointestinal (GI) bleeding effectively and with ease1,2,3 --
-- Nexpowder™* endoscopic hemostasis system showed a lower rebleeding rate and has nearly double the adhesive force of other hemostatic sprays2,3 --
-
Sep 21, 2022
Medtronic been ranked fifth in the 2022 Best Workplaces in Asia list by Great Place to Work, the global authority on workplace culture. This is a significant improvement of six places from 2021....
-
Sep 21, 2022
Bifurcation using Onyx Frontier DES Medtronic announced today that it has received Food and Drug Administration (FDA) approval for the treatment of non-left main bifurcation lesions utilizing the...
-
Sep 20, 2022
Medtronic announced today that it recently received CE mark for its Radiant™ balloon-expandable covered stent, the first and currently only covered stent indicated for use in ChEVAR with the...
-
Sep 18, 2022
TCT 2022: Late-breaking data from Intrepid™ Pilot Study 3-year follow-up & 1-year follow-up from Transfemoral EFS study demonstrate promising valve performance Medtronic today announced new data...








